Feb. 15, 2013
-- In addition to enabling faster, easier access to ClinicalTrials.gov and EudraCT, the new platform also provides advanced analytics tailored to meet the specific needs of the pharmaceutical and biotech industries. Company President Bruno Larvol commented, “We are excited about this new product. We have worked closely with several large pharmaceutical companies to develop a user-friendly pipeline platform which focuses on specific diseases, companies and mechanisms of action.”
For more information regarding how The Larvol Group can assist your organization, please visit our booth at the conference. If you would like to schedule a meeting with Mr. Larvol during the event, please contact Sonya Williams at sonya.williams@
larvol.com or 33 (0) 762 153 314.
About Larvol Sigma: Larvol Sigma is the first free clinical trial and pipeline intelligence platform. With a database containing over 5,000 drugs as well as more than 150,000 individual drug trials across all major indications, Larvol Sigma is a comprehensive free resource for investigators, researchers and industry professionals. To preview Larvol Sigma, please visit www.larvolsigma.com.
About The Larvol Group, LLC: Founded in 2004, The Larvol Group (www.larvol.com)
is a San Francisco-based competitive intelligence company which provides innovative business intelligence services for the pharmaceutical industry. Their customized Market Intelligence Reports track relevant news, clinical trials and developments in the competitive landscape of a given indication. Drawing on the knowledge of over 100 professionals, The Larvol Group has expertise in all major therapeutic areas, including oncology, cardiovascular, metabolic diseases, CNS, immunology, women’s health and pain management. Their diverse portfolio of clients includes top pharmaceutical companies and small to midsized biotech firms.